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Background: Radiation-induced skin reaction (RISR) is a common side effect that affects the majority of cancer
patients receiving radiation treatment. RISR is often characterised by swelling, redness, pigmentation, fibrosis, and
ulceration, pain, warmth, burning, and itching of the skin. The aim of this systematic review was to assess the
effects of interventions which aim to prevent or manage RISR in people with cancer.
Methods: We searched the following databases up to November 2012: Cochrane Skin Group Specialised Register,
CENTRAL (2012, Issue 11), MEDLINE (from 1946), EMBASE (from 1974), PsycINFO (from 1806), CINAHL (from 1981)
and LILACS (from 1982). Randomized controlled trials evaluating interventions for preventing or managing RISR in
cancer patients were included. The primary outcomes were development of RISR, and levels of RISR and symptom
severity. Secondary outcomes were time taken to develop erythema or dry desquamation; quality of life; time taken
to heal, a number of skin reaction and symptom severity measures; cost, participant satisfaction; ease of use and
adverse effects. Where appropriate, we pooled results of randomized controlled trials using mean differences (MD)
or odd ratios (OR) with 95% confidence intervals (CI).
Results: Forty-seven studies were included in this review. These evaluated six types of interventions (oral systemic
medications; skin care practices; steroidal topical therapies; non-steroidal topical therapies; dressings and other).
Findings from two meta-analyses demonstrated significant benefits of oral Wobe-Mugos E for preventing RISR
(OR 0.13 (95% CI 0.05 to 0.38)) and limiting the maximal level of RISR (MD −0.92 (95% CI −1.36 to −0.48)). Another
meta-analysis reported that wearing deodorant does not influence the development of RISR (OR 0.80 (95% CI 0.47
to 1.37)).
Conclusions: Despite the high number of trials in this area, there is limited good, comparative research that
provides definitive results suggesting the effectiveness of any single intervention for reducing RISR. More research is
required to demonstrate the usefulness of a wide range of products that are being used for reducing RISR. Future
efforts for reducing RISR severity should focus on promising interventions, such as Wobe-Mugos E and oral zinc.
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Radiation treatment remains an essential treatment for
people with cancer and is associated with a number of
short-term and long-term side-effects [1,2]. One of these
side-effects is radiation-induced skin reaction (RISR), af-
fecting up to 95% of people receiving radiation treatment
for their cancer [3]. The reactions are a result of radiation
treatment disrupting the normal process of cell division
and regeneration, resulting in cell damage or cell death
[4]. The damage can be a result of several processes, in-
cluding a reduction of endothelial cell changes, inflamma-
tion, and epidermal cell death [5]. Radiation-induced skin
reactions are often characterised by swelling, redness,
pigmentation, fibrosis, and ulceration of the skin. Signs
and symptoms are expressed as pain, warmth, burning,
and itching of the skin [6]. The development of RISR
may occur two to three weeks after treatment commences,
and may persist up to four weeks after the treatment ends
[7]. The factors influencing the development or severity of
RISR have been classified in the literature as either being
intrinsic or extrinsic [8]. Intrinsic factors include age, gen-
eral health, ethnic origin, coexisting diseases, UV expos-
ure, hormonal status, tumour site [8], and genetic factors
[9]. Extrinsic factors include the dose, volume and fraction
of radiation, radio-sensitisers, concurrent chemotherapy,
and the site of treatment. These factors can be more
broadly categorised into radiation treatment-related, gen-
etic, and personal factors [3].
Interventions can be generally viewed as either prevent-
ive or management strategies [10]. Preventive strategies
may include minimising irritants or irritations to the irradi-
ated skin such as those associated with particular hygiene
regimens, minimising friction, reducing the frequency of
washing, avoiding the use of soap, cream and deodorants,
and avoiding sun exposure [4,11]. Management strategies
for established reactions may include active management
of any reddening of the skin (erythema), any dry or moist
shedding of the skin (desquamation), and ulceration of
the skin, with topical preparations and dressings [8,10].
Erythema is defined as the redness caused by flushing of
the skin due to dilatation of the blood capillaries in the
dermis [12]. Dry desquamation is the shedding of the
outer layers of the skin and moist desquamation occurs
when the skin thins and then begins to weep as a result
of loss of integrity of the epithelial barrier and a decrease
in pressure exerted by plasma proteins on the capillary
wall [13].
Radiation-induced skin reactions have an impact on
the level of pain/discomfort experienced and the quality
of life of those who undergo radiation treatment [2], and
may even require changes to the person’s radiation
schedule (if severe) [14]. In some cases, complex surgical
reconstruction of damaged skin may be required [15].
Therefore, managing skin reactions is an importantpriority in caring for those who undergo radiation treat-
ment [6]. Presently, a number of inconsistencies exist
across radiation treatment centres globally with regard to
the practice and recommendations given by health profes-
sionals to both prevent and manage this often painful
side-effect of radiation treatment [8,10,16].
Efforts to guide practice in this area have led to the
publication of seven systematic reviews [17-23]. We re-
cently overviewed this literature and found conflicting
conclusions and recommendations for practice [24,25].
There were also a number of methodological issues in
many of reviews that we appraised, including the lack of
duplicate assessment of study eligibility, inclusion of stud-
ies other than RCTs, lack of publication bias assessment,
lack of declaration of conflict of interest, and inappropri-
ate use of meta-analysis [24,25]. Consequently, we believed
there was still a need for a high quality systematic review
of interventions to prevent and manage RISR. Therefore,
the aim of this systematic review was to assess the effects
of interventions for preventing and managing RISR in
people with cancer.
Methods
Inclusion criteria
All randomized controlled trials (RCT) providing a com-
parison between intervention types or a comparison be-
tween intervention and no intervention (usual care group)
were considered. Participants were those receiving exter-
nal beam radiation treatments. There were no restrictions
on age of the participants, gender, diagnosis, previous or
concurrent therapies, health status, dosage of treatment,
location of irradiated area, or the setting where they re-
ceived their radiation treatment. Studies which compared
an intervention with the aim of preventing or managing
RISRs were eligible. The inclusiveness of definitions of
participants and interventions ensured that this review
would be of use both to those in clinical practice as well
as the wider population. Trials reporting the outcomes
of interest listed below were included.
Data sources, searches and study selection
We aimed to identify all relevant RCTs regardless of
language or publication status (published, unpublished,
in press, and in progress). We searched the following
electronic databases: The Cochrane Skin Group Specia-
lised Register, The Cochrane Central Register of Con-
trolled Trials (CENTRAL) on The Cochrane Library
(Issue 11, 2012), MEDLINE Ovid (1946 to 14/11/2012),
EMBASE Ovid (1974 to 14/11/2012), PsycINFO Ovid
(1806 to 14/11/2012), CINAHL EBSCO (1982 to 14/11/
2012), and LILACS (1982 to 14/11/2012) (Please see
Additional file 1). With reference to Additional file 1,
we also searched trial registers, reference lists reported in
relevant reviews and studies which were not identified via
Table 1 Primary and secondary outcomes of the review
Outcome
classification
Outcome description
Primary Prevention
The development of a radiation-induced skin
reaction (yes/no).
Treatment
Level of skin toxicity/reactions at one week and two
weeks following the onset of the skin reaction.
Level of symptom severity at one week and two weeks
following the onset of the skin reaction (physical or
psychological).
Secondary Prevention
Time taken to develop an erythema or dry
desquamation.
Treatment
Quality of life.
Time taken to heal.
Level of skin toxicity/reactions at the completion of
treatment and at the last follow-up.
Maximum level of skin toxicity/reactions reported.
Level of symptom severity at any time following the onset
of treatment (physical or psychological), at the completion
of radiation treatment and at the last follow-up.*
Maximum level of symptom severity (physical or
psychological) reported.*
Prevention and Treatment
Cost of the interventions (both direct and indirect cost,
both to the participant and the health system).
Participant satisfaction.
Ease of use.
Adverse effects (including allergic reactions).
*All symptoms reported by eligible trials were included.
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(from inception to November 2012) for articles about
interventions that aim to prevent or manage RISRs, ab-
stracts from relevant conference proceedings, as well as
the ProQuest Dissertations and Theses database.
Two review authors (RC and JW) independently pre-
screened all search results (titles and abstracts) for
possible inclusion based on the inclusion criteria, and
those selected by either or both authors were subject
to full-text assessment. These same two review authors
independently assessed the selected articles against the
inclusion criteria, and resolved any discrepancies by
consensus. In this process, no arbiter was required. Studies
that were excluded after full-text assessment are listed in
Additional file 2, giving reasons for exclusion.
Outcomes (Primary and Secondary)
Outcomes were classified as being related to either pri-
mary or secondary, and prevention or treatment (Table 1).
We defined the primary outcome measures in this review
as the development of RISR (Yes/No); the level of skin
toxicity/reactions at one week and two weeks following
the onset of the skin reaction; and the level of symptom
severity at one week and two weeks following the onset of
the skin reaction. During the review, we adjusted the time
points of the secondary outcomes established in our re-
view protocol. This was due to the difficulty of measuring
the commencement of skin reactions of every trial partici-
pants. These outcome measures at the pre-specified time
points were too restrictive and possibly unrealistic. These
additional time points allow the inclusion of the average
grading of RISR/ other symptom severity at certain weeks
following the commencement of radiation treatment (e.g.
maximum RISR throughout the treatment, at five or six
weeks of radiation treatment, at completion of radiation
treatment (usually between five to seven weeks), or at the
last follow-up appointment (usually two weeks or four
weeks after the completion of radiation treatment)). The
maximum level of RISR represents the worst reaction as-
sociated with a given intervention or no intervention at
all. These commonly reported outcome measures at these
specific time points are considered clinically important, as
the radiation dose reaches its highest accumulative level at
the completion of radiation treatment.
Data extraction
A data extraction form (see Additional file 3) was devel-
oped, piloted (with three studies) and amended. Two indi-
viduals, with at least one being RC or JW, independently
extracted data using the data extraction form for each
study. Any errors or inconsistencies were resolved after
consulting the original source and consensus. RC entered
the data into RevMan 5, with JW and LM checking the
accuracy of all data entry.Risk of bias assessment
We assessed and reported on the risk of bias of included
studies in accordance with the guidelines in the Cochrane
Handbook for Systematic Reviews of Interventions [26],
which recommends the explicit reporting of individual
domains including sequence generation, allocation con-
cealment, blinding of participants, personnel and outcome
assessors, incomplete outcome data, selective reporting,
and other sources of bias. Two review authors independ-
ently assessed the risk of bias in included studies, with any
disagreements resolved by discussion and consensus. This
led to an overall assessment of the risk of bias of the in-
cluded studies [27]. We assessed each of the risk of bias
items as low, high, or unclear.
Data synthesis and analysis
We analysed data using The Cochrane Collaboration’s
Review Manager 5 (RevMan 5). We examined the data
from included studies for descriptive synthesis and pooled
Figure 1 Study flow diagram.
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methodology, and outcomes. At the protocol stage, it was
expected that interventions might be classified as either
preventative or management strategies [10], and that the
interventions could be used for either or both purposes
[17]. We have reported the data according to the defini-
tions of included outcomes (whether preventative or man-
agement in nature) in this review. We considered studies
with less than 100 participants small, studies with between
101 to 200 participants medium and studies with more
than 201 participants large.
If included studies were sufficiently similar in terms of
population, inclusion criteria, interventions and/or out-
comes (including the time(s) at which these were assessed
throughout the radiation regimen), we considered pooling
the data statistically using meta-analysis. These were re-
ported as pooled mean differences (MD) or Standardised
mean differences (SMD) (continuous variables), or odds
ratios (OR) (dichotomous variables) and corresponding
95% confidence interval (CI). Numbers needed to treat
(NNT) for benefit or harm was not calculated due to the
low number of meta-analysis conducted in this review.
For survival data, we used hazard ratios and correspond-
ing 95% CI for comparison. If any data was not quoted
in studies, then we requested these from authors. Alter-
natively, we attempted to calculate this from available
summary statistics (observed events, expected events,
variance, confidence intervals, P values, or survival curves)
according to the methods proposed by Parmer and col-
leagues [28]. However, this was not always possible due to
the lack of data provided in the paper/by authors despite
attempts to contact them for this information.
Heterogeneity was tested using the I2 statistic (which
was used to describe the percentage of the variability in ef-
fect estimates that was due to heterogeneity rather than
sampling error). A value greater than 50% was considered
to represent substantial heterogeneity [26], and we ex-
plored heterogeneity and possible reasons. We undertook
random-effects analyses if I2 was greater than 50%. With
regards to the assessment of publication bias, it is recom-
mended that a funnel plot should only be constructed
when there are at least 10 studies in a meta-analysis [26].
Therefore, we did not construct a funnel plot to assess the
possibility of publication bias because there were too few
trials per meta-analysis (all <3).
Results
Study selection
The different steps of the electronic search are illustrated
in Figure 1. In total, we identified 4857 citations from the
electronic database searches after removing the duplicates.
After we screened all the titles and abstracts, 105 articles
were potentially relevant and we retrieved them in full
text. Of these 105 titles, we included 47 studies involving5688 participants and excluded 58 which did not meet the
selection criteria. The characteristics of all included stud-
ies are included in Additional file 4. Classification of in-
cluded studies by countries or regions is illustrated in
Figure 2, with the majority of studies coming from North
America (n = 16). In addition, sample size variation be-
tween trials is illustrated in Figure 3. The majority (n = 29)
of studies included fewer than 100 patients (small). Twelve
trials included 101–200 participants (medium), and six
trials included over 201 participants (large), with a max-
imum number of participants being 547. All studies
were undertaken with adult patients except for one that
included patients between three and 21 years of age [29].
Of the 47 included studies, six trials investigated the
effects of oral systemic therapies [30-35]; two examined
57
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Figure 2 Number of included studies by country or region.
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antiperspirant use [38-41]; five examined steroidal topical
therapies [42-46]; 23 examined non-steroidal topical
therapies [11,29,47-67]; six examined dressing interven-
tions [68-73]; and one examined light emitting diode
photo-modulation [74].
Risk of bias assessment
Risk of bias assessment is reported in Figure 4. Thirty-six
studies were considered high risk of bias (plausible bias that
seriously weakens confidence in the results), because one
or more domains received a judgement of high risk
[11,29,30,32-34,36-43,48-50,52-60,62-64,67-73]. Ten studies
were rated as unclear risk of bias (plausible bias that raises
some doubt about the result) because one or more criteria
were assessed as unclear [35,44-47,51,61,65,66,74]. One
study [31] was considered low risk of bias, because all
domains received a judgement of low risk (see Figure 4).29
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Figure 3 Number of included studies sample size.With regards to allocation concealment (selection bias),
the method used to generate the allocation sequence was
clearly described in 22 studies [31,32,35,37,39-41,43,45,
47,50-53,55,56,59,63,68,69,71,72], but not in the 25
remaining studies. Of the 47 studies, 22 studies adequately
reported allocation concealment [31,32,35,37,39-41,43,45,
47,50-53,55,56,59,63,68,69,71,72]. The method used to
conceal the allocation sequence was not reported in the
remaining studies, thus receiving a judgement of unclear
risk of bias for this domain.
Performance and detection bias, blinding for participants
and personnel from knowledge of which intervention a par-
ticipant received was achieved in a number of placebo tri-
als. All other open label trials and trials that compared a
single intervention and usual care/institutional preferences
received a judgement of high risk for this domain. Of
the 47 studies, 16 studies described in sufficient detail
how blinding of participants and personnel was achieved3 3
201 to 300 over 301
ple size
ies by sample size
Figure 4 Risk of bias summary: review authors’ judgements
about each risk of bias item for each included study.
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come assessors was sufficiently described in 21 studies
[31,34,35,38,40,41,44-47,50-52,55,56,59-61,68,71,74]. The
remaining studies either did not have adequate reporting
of how blinding was achieved or did not blind the partici-
pants, personnel and/or outcome assessors at all.
With regards to attrition bias, incomplete outcome data
appears to have been adequately addressed in 21 studies
[11,31-33,35,37,41,44,46,47,50,51,54,57,59-61,63,67,70,74].
Outcomes were reasonably well-balanced across inter-
vention groups/control groups, with similar reasons for
missing data across the groups and intention-to-treat
analysis conducted. However, in 14 studies, there were
concerns about unbalanced groups with missing data or
the lack of intention-to-treat analysis [29,30,34,36,39,40,
52,53,55,56,68,69,72,73]. The remaining 12 studies did
not provide sufficient information to allow for a clear
judgement of the risk of bias for this domain.
In terms of selective reporting (reporting bias), the pro-
tocols were not available for any of the included studies.
Based on the information in the methods section of the re-
ports, 33 studies appear to have reported all pre-specified
outcomes and were therefore judged to be free of select-
ing reporting [11,30-35,38-40,42-49,51-57,60-63,68,70,72,73].
The remaining 14 studies were judged to be unclear or
high bias. In the judgement of risk of bias for this domain,
we also took into consideration whether trials reported on
some of the important and expected outcomes such as
RISR severity, pain and itch. Studies that did not report
these outcomes received a judgement of unclear risk of
bias.
For other potential sources of bias, we judged as un-
clear or high risk of bias in 18 studies (e.g. declarations
of potential conflicts of interest or funding support were
frequently unreported, or the report did not clearly state
to what extent any support might have posed a risk of
bias) [33,36,41-43,47,50,51,53,55,58,61,62,68-71,74]. The
included studies received a low risk of bias if no other
potential threats to validity were identified.
Data synthesis
Table 2 outlines the results of all analyses carried out for
the purpose of this review. However, results of particular
interest pertaining to both prevention and treatment
interventions are summarized below.
Prevention of radiation-induced skin reactions
Oral systemic therapies
One fixed effect meta-analysis including 219 partici-
pants from two unblinded RCTs [32,33] suggested that
the odds of developing a RISR was 87% lower for people
receiving oral Wobe-Mugos E (proteolytic enzymes con-
taining 100 mg papain, 40 mg trypsin, and 40 mg chymo-
trypsin) (three tablets) than no medication (OR 0.13, 95%
Table 2 Summary of results
Comparison of interventions Included studies,
sample size and
treatment areas
Outcome
type
Outcome Results/effect size
1. Oral systemic medications
1.1 Oral Wobe-Mugos versus no
medication
Dale, 2001; Gujral,
2001 N = 219
Prevention Primary
Development of RISR (Yes/No) (Dale,
2001 & Gujral, 2001)
Meta-analysis:
OR 0.13, 95% CI 0.05 to 0.38,
p < 0.0005
(Favouring Oral Wobe-Mugos)
Treatment Secondary
Maximum Levels of RISR (RTOG/EORTC
criteria, with a possible range of 0–4)
(Dale, 2001 & Gujral, 2001)
Meta-analysis:
MD −0.92, 95% CI −1.36 to −0.48,
p < 0.0001
(Favouring Oral Wobe-Mugos)
1.2 Oral Pentoxifylline versus no
medication
Aygenc, 2004 Prevention Primary
N = 78 Development of RISR (Yes/No) OR 0.18, 95% CI 0.01 to 3.95, p = 0.28
Treatment Secondary:
Adverse Effects (Yes/No) OR 17.24, 95% CI 0.95 to 313.28,
p = 0.05
1.3 Oral Antioxidant versus placebo Bairati, 2005 Treatment Secondary: MD −0.06, 95% CI −0.15 to 0.03,
p = 0.17
N = 545 RISR at the end of radiation treatment
(RTOG criteria, with a possible range
of 0–4)
RISR at four weeks after the end of
radiation treatment (RTOG criteria,
with a possible range of 0–4)
MD 0.00, 95% CI −0.08 to 0.08,
p = 1.00
Global quality of life at the end of
radiation treatment (QoLC30, with a
possible range of 0–100)
MD 0.00, 95% CI −3.95 to 3.95,
p = 1.00
Global quality of life at four weeks
after the end of radiation treatment
(QoLC30, with a possible range of
0–100)
MD −2.00, 95% CI −5.29 to 1.29,
p = 0.23
Skin-related quality of life at the end
of radiation treatment (HNC-QoL, with
a possible range of 0–7 with 7
representing better quality of life)
MD 0.10, 95% CI −0.16 to 0.36.
p = 0.46
Skin-related quality of life at weeks
after the end of radiation treatment
(HNC-QoL, with a possible range of
0–7 with 7 representing better quality
of life)
MD 0.00, 95% CI −0.12 to 0.12,
p = 1.00
1.4 Oral sucralfate suspension versus
placebo
Lievens, 1998 Treatment Secondary:
N = 83 Maximum levels of RISR (Scoring
system developed by authors, with a
possible range of 0–6)
MD 0.20, 95% CI −0.34 to 0.74,
p = 0.47
Adverse effect (measured as mean
peak nausea, scoring system
developed by authors, 0 = none,
4 = vomiting resistant to medication)
MD −0.22, 95% CI −0.61 to 0.17,
p = 0.27
1.5 Oral zinc supplementation versus
placebo
Lin, 2006 Treatment Secondary:
N = 97 RISR at the completion of radiation
treatment (RTOG criteria, with a
possible range of 0–4)
MD −0.50, 95% CI −0.58 to −0.42,
p < 0.00001
(Favouring oral zinc
supplementation)
Chan et al. BMC Cancer 2014, 14:53 Page 7 of 19
http://www.biomedcentral.com/1471-2407/14/53
Table 2 Summary of results (Continued)
2. Skincare practices (washing practices and deodorant use)
2.1 Washing with soap versus no
washing
Campbell, 1992;
Roy, 2001
Prevention Primary:
Development of RISR (Yes/No) (Roy,
2001)
OR 0.32, 95% CI 0.01 to 8.05, p = 0.49
N = 167
Treatment Secondary:
Itch at the end of treatment (week
six) and the two-week follow-up
(week eight) (EORTC/RTOG criteria,
with a possible score of 0–3)
(Campbell, 1992)
Week 6- MD −0.43, 95% CI −0.97 to
0.11, p = 0.12,Week 8- MD-0.40, 95%
CI −0.81 to 0.01, p = 0.06 (Favouring
washing with soap)
Erythema at the end of treatment
(week six) and the two-week follow-
up (week eight) (EORTC/RTOG criteria,
with a possible score of 0–3)
(Campbell, 1992)
Week 6- MD-0.40 95% CI −0.77 to
−0.03, p = 0.03, Week 8-MD −0.21,
95% CI −0.52 to 0.10, p = 0.18
Desquamation at the end of
treatment (week six) and the two-
week follow-up (week eight) (EORTC/
RTOG criteria, with a possible score of
0–3) (Campbell, 1992)
Week 6- MD −0.47, 95% CI −0.83 to
−0.11, p = 0.01, Week 8- MD −0.82,
95% CI −1.16 to −0.48, p < 0.00001
(Favouring washing with soap)
2.2 Washing with water versus no
washing
Campbell, 1992 Treatment Secondary:
N = 58 Itch at the end of treatment (week
six) and the two-week follow-up
(week eight) (EORTC/RTOG criteria,
with a possible score of 0–3)
Week 6- MD −0.27, 95% CI −0.83 to
0.29, p = 0.35, Week 8- MD −0.46,
95% CI −0.83 to −0.09, p = 0.01
(Favouring washing with water)
Erythema at the end of treatment
(week six) and the two-week follow-
up (week eight) (EORTC/RTOG criteria,
with a possible score of 0–3)
Week 6- MD −0.34, 95% CI −0.69 to
0.01, p = 0.06, Week 8- MD −0.44,
95% CI −0.72 to −0.16, p = 0.002
(Favouring washing with water)
Desquamation at the end of
treatment (week six) and the two-
week follow-up (week eight) (EORTC/
RTOG criteria, with a possible score of
0–3)
Week 6- MD −0.59, 95% CI −0.94 to
−0.24, p = 0.001, Week 8- MD −0.62,
95% CI −0.96 to −0.28, p = 0.0004
(Favouring washing with water)
2.3 Washing with water versus
washing with soap
Campbell, 1992 Treatment Secondary:
N = 64 Itch at the end of treatment (week
six) and the two-week follow-up
(week eight) (EORTC/RTOG criteria,
with a possible score of 0–3)
Week 6- MD 0.16, 95% CI −0.35 to
0.67, p = 0.54, Week 8- MD −0.06,
95% CI −0.39 to 0.27, p = 0.72
Erythema at the end of treatment
(week six) and the two-week follow-
up (week eight) (EORTC/RTOG criteria,
with a possible score of 0–3)
Week 6- MD 0.06, 95% CI −0.26 to
0.38, p = 0.71, Week 8- MD −0.44,
95% CI −0.72 to −0.16, p = 0.001
(Favouring washing with water)
Desquamation at the end of
treatment (week six) and the two-
week follow-up (week eight) (EORTC/
RTOG criteria, with a possible score of
0–3)
Week 6- MD −0.12, 95% CI −0.51 to
0.27, p = 0.54, Week 8- MD 0.20, 95%
CI −0.16 to 0.56, p = 0.27
2.4 Deodorant versus no deodorant Bennett, 2009;
Gee, 2000;
Theberge, 2009;
Watson, 2012
Prevention Primary:
Development of RISR (Yes/No)
(Bennett, 2009 & Gee, 2000)
Meta-analysis:
OR 0.80, 95% CI 0.47 to 1.37, p = 0.42
Development of RISR in patients with
axilla treated (Yes/No) (Bennett, 2009)
OR 0.06, 95% CI 0.01 to 0.60, p = 0.02
N = 509 Treatment Secondary:
RISR at the end of radiation treatment
and at the two-week follow-up
(CTCAE criteria version 3, with a
possible range of 0–3) (Watson, 2012)
End of treatment- MD 0.01, 95% CI
−0.17 to 0.19, p = 0.91, Two-week
follow-up- MD 0.01, 95% CI −0.21 to
0.23, p = 0.93
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Table 2 Summary of results (Continued)
Maximum RISR rated by researcher
(RTOG criteria, with a possible range
of 0–3) (Bennett, 2009)
MD = −0.74, 95% CI −1.22 to −0.26, p
= 0.003
(Favouring deodorant)
Moderate-to-severe pain at the end of
radiation treatment and at the two-
week follow-up (Yes/No) (Theberge,
2009)
End of treatment- OR 0.77, 95% CI
0.29 to 2.09, p = 0.61, Two-week
follow-up- OR 2.16, 9% CI 0.65 to
7.14, p = 0.21
Pruritus at the end of radiation
treatment and at the two-week
follow-up (Yes/No) (Theberge, 2009)
End of treatment- OR 2.62, 95% CI
1.01 to 6.78, p = 0.05, Two-week
follow-up- OR 1.47, 95% CI 0.57 to
3.77, p = 0.42
Sweating at the end of radiation
treatment and at the two-week
follow-up (Yes/No) (Theberge, 2009)
End of treatment- OR 0.34, 95% CI
0.12 to 0.93, p = 0.04, Two-week
follow up- OR 0.70, 95% CI 0.25 to
1.99, p = 0.51
3. Steroidal topical ointment/cream
3.1 Topical 0.1% mometasone
furoate cream versus placebo
Miller, 2011 Prevention Primary:
N = 166 Development of RISR (Yes/ No) OR 0.60, 95% CI 0.28 to 1.31, p = 0.20
Treatment Secondary:
RISR at the two-week follow-up after
the completion of radiation treatment
(CTCAE criteria version 3.0, with a
possible range of 0–3)
MD −0.39, 95% CI −0.80 to 0.02,
p = 0.06
Maximum RISR level (CTCAE criteria
version 3.0, with a possible range of
0–3)
MD −0.10, 95% CI −0.35 to 0.15,
p = 0.43
3.2 Topical betamethasone cream
versus placebo
Omidvari, 2007 Prevention Primary:
N = 36 Development of RISR (Yes/No) There was an equal proportion of
people developing a RISR (summary
statistics not estimated)
Treatment Secondary:
RISR at the end of treatment (week
five) and the two-week follow-up
(week seven) (RTOG criteria, with a
possible range of 0–4)
End of treatment- MD −0.10, 95% CI
−0.28 to 0.08, p = 0.28, two-week
follow-up- MD −0.55, 95% CI −0.71 to
−0.39, p < 0.00001 (Favouring topical
betamethasone cream)
Maximum level of RISR (RTOG criteria,
with a possible range of 0–4)
MD −1.62, 95% CI −2.03 to −1.21, p
< 0.00001 (Favouring topical
betamethasone cream)
3.3 Topical betamethasone versus no
topical treatment
Omidvari, 2007 Prevention Primary:
N = 36 Development of RISR (Yes/ No) There was an equal proportion of
people developing a RISR (summary
statistics not estimated)
Treatment Secondary:
RISR at the end of treatment (week
five) and two weeks after treatment
(week seven) (RTOG criteria, with a
possible range of 0–4)
End of treatment- MD −0.40, 95% CI
−0.62 to −0.15, p = 0.002, two-week
follow-up- MD −0.30, 95% CI −0.53 to
−0.07, p = 0.01
(Favouring topical betamethasone
cream)
Maximum level of RISR (RTOG criteria,
with a possible range of 0–4)
MD −0.27, 95% CI −0.75 to 0.21,
p = 0.27
3.4 Topical corticosteroid versus
another topical corticosteroid
Glees, 1979 Prevention Primary:
N = 53 Development of RISR (Yes/ No) OR 3.35, 95% CI 0.13 to 86.03,
p = 0.46
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3.5 Topical corticosteroid plus
antibiotics versus corticosteroid
alone
Halnan, 1962 Prevention Primary:
N = 20 Development of RISR (Yes/ No) There was an equal proportion of
people developing a RISR (summary
statistics not estimated)
3.6 Topical corticosteroid plus
antibiotics versus no treatment
Halnan, 1962 Prevention Primary:
N = 20 Development of RISR (Yes/ No) OR 0.07, 95% CI 0.01 to 0.84, p = 0.04
(Favouring topical corticosteroid plus
antibiotics)
3.7 Topical corticosteroid versus
dexpanthenol
Schmuth, 2002 Treatment Secondary:
N = 21 Levels of RISR at the end of radiation
treatment (week six) (The clinical
symptom score with a possible range
of 0–3)
MD −0.10, 95% CI −0.57 to 0.37,
p = 0.68
Levels of RISR at the two-week follow-
up after the end of radiation treatment
(week eight) (The clinical symptom
score with a possible range of 0–3)
MD −1.40, 95% CI −1.97 to −0.83,
p < 0.00001
(Favouring topical corticosteroid)
4. Dressings
4.1 Hydrogel dressing versus Gentian
violet dressing
Gollins, 2008 Treatment Secondary:
N = 20 Time to heal (days) HR 7.95, 95% CI 2.20-28.68, p = 0.002
(Favouring hydrogel dressing)
Adverse events (measured as stinging,
yes or no)
OR 3.89, 95% CI 0.62 to 24.52,
p = 0.15
4.2 Gentian violet dressing versus
non-adherent dressing
Mak, 2005 Treatment Secondary:
N = 39 Time to heal (days) HR 0.73, 95% CI 0.52-1.03, p = 0.07
Pain at week two after the
application of dressing (Scoring system
developed by authors, with a possible
range of 0–5)
MD −0.29, 95% CI = −0.66 to 0.08,
p = 0.13
4.3 Silver nylon dressing versus
standard care
Niazi, 2012 RISR severity at the end of radiation
treatment (CTCAE criteria version 4,
with a possible range of 0–4)
MD = −0.86, 95% CI −1.59 to −0.13, p
= 0.02
N = 40 (Favouring silver nylon dressing)
4.4 MVP dressings versus Lanolin
dressing
Shell, 1986 Shell 1986 compared moisture vapour permeable (MVP dressing) compared with lanolin
dressings. We were unable to extract data from the study. Insufficient information was
provided in relation to the time to healing outcome as well as the RISR scores (no SD
provided). The trial authors reported “the trend to faster healing in the MVP group was
not statistically significant”.
N = 16
4.5 Mepilex lite dressing versus
aqueous cream
Paterson, 2012 Paterson 2012 compared Mepilex lite dressing with aqueous cream alone. We were
unable to extract data from the study. However, the trial authors reported that ”Mepilex
Lite dressings did not significantly reduce the incidence of moist desquamation, but did
reduce the overall severity of skin reactions by 41% (p < 0.001), and the average moist
desquamation score by 49% (p = 0.043).“ The trial authors were contacted for further
information. However, no replies were received at the time of publishing this review.
N = 74
5. Non-steroidal ointment/cream
5.1 Hyaluronic acid versus placebo
cream
Kirova, 2011;
Leonardi, 2008;
Liguori, 1997;
Primavera, 2006
Prevention Primary:
Development of RISR (Yes/No)
(Leonardi, 2008)
OR 0.39, 95% CI 0.01 to 10.10,
p = 0.57
Treatment Secondary:
Severe pain (>2) at week one, week
two and week three of radiation
treatment (as defined as >2 on a
visual analogue scale, Yes/No) (Kirova
2011)
Week One- OR 1.25, 95% CI 0.67 to
2.32, p = 0.49, Week Two- OR 1.79,
95% CI 0.97 to 3.27, p = 0.06, Week
Three- OR 1.30, 95% CI 0.66 to 2.59, p
= 0.45
N = 384
Quality of life at week four of
radiation treatment (EORTC CLC Q30)
(Kirova 2011)
MD −0.10, 95% CI −6.75 to 6.55,
p = 0.98
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RISR severity at the end of radiation
treatment (Scoring system developed
by authors, with a possible range of
0–6) (Liguori 1997)
MD −0.73, 95% CI −1.04 to −0.42,
p < 0.00001
(Favouring hyaluronic acid)
RISR severity at four weeks after
radiation treatment completion
(Scoring system developed by
authors, with a possible range of 0–6)
(Liguori 1997)
MD −0.35, 95% CI −0.68 to −0.02,
p = 0.04
(Favouring hyaluronic acid)
Maximum RISR over the duration of
radiation treatment (CTCAE, with a
possible range of 0–4) (Leonardi, 2008)
MD-0.95, 95% CI −1.23 to −0.67,
p < 0.00001
(Favouring hyaluronic acid)
Pain, itching and burning at four weeks
of radiation treatment (0–10 cm visual
analogue scale, with a possible range
of 0–10) (Leonardi, 2008)
Pain- MD −0.50, 95% CI −1.72 to 0.72,
p = 0.42, Itching- MD −0.18, 95% CI
−1.39 to 1.03, p = 0.77, Burning- MD
−0.91, 95% CI −2.01 to 0.19, p = 0.10
Adverse effects (yes/no) (Leonardi, 2008) OR 0.17, 95% CI 0.02 to 1.65, p = 0.13
5.2 Aloe vera versus aqueous cream Heggie, 2002 Heggie 2002 reported that “aqueous cream was significantly better than aloe vera in
reducing dry desquamation and pain related to treatment”. However, this study did not
contain data or summary statistics concerning the outcomes as defined by this review.N = 225
5.3 Aloe vera gel and soap versus
soap alone
Olsen, 2001 Olsen 2001reported that “when the cumulative of radiation dose was high (>2700 cGy),
the median time was give weeks prior to any skin changes in the aloe/soap arm versus
three weeks in the soap only arm. When cumulative dose increases over time, there
seems to be a protective effect of adding aloe to the soap regimen.” However, this study
did not contain data or summary statistics concerning the outcomes as defined by this
review.
N = 73
5.4 Aloe vera gel versus placebo Williams, 1996 Williams 1996 reported that “skin dermatitis scores were virtually identical on both
treatment arms, and that, aloe vera gel does not protect against radiation treatment-
induced dermatitis”. However, this study did not contain data or summary statistics
concerning the outcomes as defined by this review.
N = 194
5.5 Aloe vera gel versus an Anionic
Phospholipid-Based (APP) cream
Merchant, 2007 Merchant 2007 (n = 194) reported that statistically significant differences were found
favouring the APP cream over the aloe vera gel in a number of outcomes including skin
comfort, RISR skin severity. However, this study did not contain data or summary statistics
concerning the outcomes as defined by this review.
N = 194
5.6 Trolamine versus usual care as
per institutional preference
Elliott, 2006;
Fisher, 2000
Prevention Primary:
Development of RISR (yes/no) (Elliot
2006)
OR 0.40, 95% CI 0.08 to 2.11, p = 0.28
N = 462 Treatment Secondary:
Maximum levels of RISR (NCI CTC
criteria and RTOG criteria, with a
possible range of 0–4) (Eilott, 2006 &
Fisher,2000)
Meta-analysis:
MD 0.00, 95% CI −0.13 to 0.13,
p = 0.97
5.7 Trolamine versus Placebo Gosselin, 2010 Patient satisfaction (Scoring system
developed by authors, with a possible
range of 0–5, 5-best satisfaction)
MD 1.12, 95% CI 0.56 to 1.68,
p < 0.00001 (Favouring trolamine)
N = 102
Ease of use (Scoring system
developed by authors, with a possible
range of 0–5, 5-highest level of ease)
MD 0.44, 95% CI 0.01 to 0.87,
p = 0.04
(Favouring trolamine)
5.8 Trolamine versus Calendula Pommier, 2004 Treatment Secondary: OR 7.68, 95% CI 3.07 to 19.17,
p < 0.0001
N = 254 Ease of use (measured as difficult to
use- yes or no)
(Favouring trolamine)
Allergic reaction (yes/no) OR 0.11, 95% CI 0.01 to 2.05, p = 0.14
5.9 Trolamine versus ETA Gel (99%
Avene Thermal Spring Water)
Ribet, 2008 Treatment Secondary:
N = 54 RISR severity at the end of radiation
treatment (NCI CTC criteria, with a
possible range of 0–4)
MD −0.14, 95% CI −0.58 to 0.30,
p = 0.53
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5.10 Trolamine versus topical
Qingdiyou medication
Zhang, 2011 Zhang 2011 compared trolamine and topical qingdiyou medication. We could not extract
data from this study. The trial authors reported that patients who received qingdiyou
medication had significantly less severe RISR (p < 0.05). The trial authors did not provide a
time point as to when the assessments were undertaken. We attempted contacted
authors for further information. However, no further information was available.
N = 72
5.11 Sorbolene versus wheatgrass
extract cream
Wheat, 2006;
Wheat, 2007
Wheat 2006 (n = 30) and Wheat 2007 (n = 20) compared Sorbolene and wheatgrass
extract cream. We could not extract data from these two studies. The trial authors did not
provide SE, SD or 95% CI for the mean scores reported. The trial authors were contacted
for further information. However, no replies were received at the time of publishing this
review. Both studies reported that there were no statistically significant differences
between the two arms with respect to the peak RISR severity or time to peak RISR rating.
The trial authors reported a statistically significant improvement in quality of life of
patients in the wheatgrass group at week five and week six of radiation treatment.
N = 50
5.12 Sucralfate mixed with Sobolene
(10% w/w (50 g of sucralfate crushed
in 500 g of sorbolene) versus
Sorbolene cream
Delaney, 1997 The trial authors of Delaney 1997 reported that mean time to healing for the sucralfate
and control groups, respectively were 14.8 days (coefficient of variation (c.v. = 70%) and
14.2 days (c.v. = 75%). The ratio of mean times to healing was 1.043 and was not
statistically different from 1. (p = 0.86, 95% CI 0.65, 1.67). Estimates of the SD could not be
calculated as it was unsure whether the c.v. data presented by the authors was based on
the log transformed time-to-heal data or the untransformed data. The trial authors
reported that “there was no statistically significant difference was found between the two
arms in either from randomisation to healing or improvement in pain score”. We could
not extract data from this study. The trial authors were contacted for further information.
However, no replies were received at the time of publishing this review.
N = 39
5.13 Sucralfate cream versus placebo
cream
Maiche, 1994 Maiche 1994 compared sucralfate cream and placebo cream. The trial authors reported
that “grade 1 and grade 2 reactions appeared significantly later on the areas treated with
sucralfate cream. Grade 2 reactions were observed highly significantly more often at four
weeks (p = 0.01) and at five weeks (p < 0.05) in favour of sucralfate. No allergic reactions
were observed in either group. No other data were available after attempts to contact trial
authors for more information.
N = 44
5.14 Sucralfate cream versus aqueous
cream
Wells, 2004 Wells 2004 compared Sorbolene and aqueous cream. We could not extract data from this
study. The trial authors did not provide SE, SD or 95% CI for the mean scores reported.
However, the authors reported that no statistically significant differences were found in
the severity of skin reactions suffered by patients in either of the treatment arms.
N = 357
5.15 Non-steroidal restitutio
restructuring cream formula A and
non-steroidal restitutio restructuring
cream formula B
Garibaldi, 2009 Prevention Primary:
N = 64 Development of RISR (yes/no) OR 0.64 95% CI 0.22 to 1.88, p = 0.41
5.16 WO1932 oil in water emulsion
versus usual care/untreated
Jenson, 2011 Treatment Secondary:
N = 66 RISR severity at the end of radiation
treatment (Oncology Nursing Society
Skin Reaction Scoring System, with a
possible range of 0–3)
MD −0.21, 95% CI −0.43 to 0.01,
p = 0.07
5.17 Aquaphor ointment versus
placebo
Gosselin, 2010 Treatment Secondary:
N = 106 Patient satisfaction (Scoring system
developed by authors, with a possible
range of 0–5, 5-best satisfaction)
MD 0.59, 95% CI 0.04 to 1.15,
p = 0.04
(Favouring aquaphor ointment)
Ease of use (Scoring system
developed by authors, with a possible
range of 0–5, 5-best level of ease)
MD −0.10, 95% CI −0.61 to 0.41,
p = 0.70
5.18 RadiaCare gel versus placebo Gosselin, 2010 Treatment Secondary:
N = 106 Patient satisfaction (Scoring system
developed by authors, with a possible
range of 0–5, 5-best satisfaction)
MD 0.91, 95% CI 0.36 to 1.46,
p = 0.001
(Favouring radiacare gel)
Ease of use (Scoring system
developed by authors, with a possible
range of 0–5, 5-best level of ease)
MD 0.16, 95% CI −0.30 to 0.62,
p = 0.49
5.19 Topical Lian Bai liquid versus no
Lian Bai liquid
Ma, 2007 Prevention Development of RISR (yes or no) OR 0.04, 95% CI 0.01 to 0.12,
p < 0.00001
N = 126 (Favouring topical lian bai liquid)
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5.20 Formulation A topical cream
(capprais spinosa, opuntia
coccinellifera and olive leaf extract)
versus no treatment
Rizza, 2010 Treatment Secondary:
N = 44 Maximum RISR over eight weeks
(modified RTOG criteria, with a
possible range of 0–4)
MD −1.17, 95% CI −1.59 to −0.75,
p < 0.00001
(Favouring formulation A topical
cream)
5.21 Formulation B topical cream
(non-steroidal water based emulsion)
versus no Treatment
Rizza, 2010 Treatment Secondary:
N = 42 Maximum RISR over eight weeks
(modified RTOG criteria, with a
possible range of 0–4)
MD −0.79, 95% CI −1.21 to −0.37,
p < 0.00001
(Favouring formulation B topical
cream)
5.22 Formulation A topical cream
(capprais spinosa, opuntia
coccinellifera and olive leaf extract)
versus formulation B topical cream
(non-steroidal water based emulsion)
Rizza, 2010 Treatment Secondary:
N = 50 Maximum RISR over eight weeks
(modified RTOG criteria, with a
possible range of 0–4)
MD −0.38, 95% CI −0.69 to −0.07,
p = 0.02
(Favouring formulation A topical
cream)
6. Other interventions
6.1 LED versus no LED treatment Fife, 2010 Prevention Primary:
N = 33 Development of RISR OR 3.83, 95% CI 0.14 to 101.07,
p = 0.42
Treatment Secondary:
Levels of RISR at week five (CTCAE
criteria version 4, with a possible
range of 0–4)
MD 0.00 95% CI −0.43 to 0.43,
p = 1.00
Note: CI, Confidence Interval; CTCAE, Common Terminology Criteria for Adverse Events; HR, Hazard Ratio; LED, Light Emitting Diode photo-modulation; MD, Mean
Difference; OR, Odds Ratio; RISR, Radiation Induced Skin Reactions; RTOG, Radiation Therapy Oncology Group; SD, Standard Deviation; SE, Standard Error.
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[32,33] had slight variation of daily dosage and days of ad-
ministration before commencement of radiation treatment.
However, one small unblinded trial of 74 participants [30]
reported that oral pentoxifylline was ineffective for prevent-
ing the development of RISR.
Washing practices and deodorant/antiperspirant use
One trial [37], using a non-blinded design with 99 partici-
pants, provided results concerning how washing practices
might contribute to the prevention of a RISR. This study
did not find any benefits of washing with soap for prevent-
ing a RISR. A fixed effect meta-analysis involving 226 par-
ticipants from two unblinded trials also did not find any
difference between using deodorant or not in the develop-
ment of a RISR [38,39] (see Figure 6).Figure 5 Forest plot of comparison: Whole-Mugos E vs usual care (noSteroidal topical treatment
Four trials [42-45] evaluated the effectiveness of a range of
topical steroidal treatments for preventing the develop-
ment RISR. Two trials [44,45] reported negative results,
suggesting betamethasone cream and 0.1% mometasone
furoate cream, in comparison with no treatment or pla-
cebo, were not effective for preventing the development
RISR. Another trial [42] also did not find any difference in
this outcome when comparing 1% hydrocortisone cream
and 0.05% clobetasone burtrate. A small trial of 20 partici-
pants [43] reported statistically significant results favour-
ing topical preparation containing prednisolone with
neomycin compared to no treatment (OR 0.07, 95% CI
0.01 to 0.84, p = 0.04). However, the results need to be
considered with caution as the latter trials [42,43] had
small sample sizes with wide confidence intervals.medication), Outcome: Development of RISR (Yes/No).
Figure 6 Forest plot of comparison: Deodorant vs non-deodorant, Outcome: Development of a RISR.
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Hyaluronic acid and trolamine were separately reported
to be ineffective for preventing the development of RISR
in two trials [48,55]. Another trial [50] also did not find
any difference between two non-steroidal “restitutio re-
structuring” preparations in this outcome. A non-blinded
trial of 126 participants [57] reported the effectiveness of
Lian Bai liquid for preventing the development of RISR.
Lian Bai liquid is consisted of Huang Lian (Rhizoma Cop-
tidis) 15 g and Huang Bai (Cortex Phellodendri) 15 g
soaked in 800 ml of water. According to the results, the
odds of developing a RISR were lower for participants re-
ceiving Lian Bai liquid than those who received no treat-
ment (OR 0.04, 95% CI 0.01 to 0.12, p < 0.00001).
LED treatment versus Sham treatment
One small blinded RCT including 33 participants [74] re-
ported no benefits of LED for reducing the development
of RISR.
Treatment of radiation-induced skin reactions
Oral systemic therapies
With regards to oral systemic therapies, one random ef-
fects meta-analysis including 219 participants from two
unblinded RCTs [32,33] suggested that the maximum
extent of RISR severity was significantly lower in those who
received oral Wobe-Mugos E (MD −0.92, 95% CI −1.36
to −0.48, p < 0.0001) (see Figure 7). Both trials used dif-
ferent dosing per day for the intervention arm. In one
trial [32], participants were prescribed three tablets ofFigure 7 Forest plot of comparison: Wobe-Mugos E vs usual care (no
measure by EORTC/RTOG, with a possible range of 0-4.oral Wobe-Mugos E four times a day, whereas participants
in the other trial [33] were prescribed three tablets of oral
Wobe-Mugos E three times a day. The findings from a
blinded RCT including 97 participants [35] reported that
25 mg oral zinc supplementation (three capsules daily)
was effective for reducing the RISR severity at the end of
radiation treatment (MD −0.50, 95% CI −0.58 to −0.42,
p < 0.00001). Of all trials evaluating the effectiveness oral
systemic therapies, none of the trials compared the effect-
iveness between dosing and administration period (e.g.
start of radiation treatment to a certain number of add-
itional days post radiation treatment). The effectiveness
of oral pentoxifylline, oral antioxidant, or oral sucralfate
suspensions for reducing symptoms related to radiation
treatment cannot be determined with the available data.
Washing practices and deodorant/antiperspirant use
In terms of washing practices, washing with soap was more
effective than not washing at all for improving a number of
outcomes including lower incidence of desquamation
[37], lower levels of erythema at week six [36] (MD-
0.40 95% CI −0.77 to −0.03, p = 0.03) and lower levels
of desquamation at the end of treatment (week six)
(MD −0.47, 95% CI −0.83 to −0.11, p = 0.01) and two
weeks follow-up (week eight) (MD −0.82, 95% CI −1.16
to −0.48, p < 0.00001) [36]. Besides, the same three-armed
trial [36] reported that washing with soap was also more
effective than washing with water for reducing the levels
of desquamation at the end of treatment (week six)
(MD −0.59, 95% CI −0.94 to −0.24, p = 0.001) and themedication), Outcome: Maximum levels of skin toxicity as
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to −0.28, p = 0.0004). Levels of itch and erythema at week
eight of radiation treatment were also lower in the soap
group. When comparing washing with water or with soap,
the only statistically significant difference observed was
erythema at week eight (MD −0.44, 95% CI −0.72 to −0.16,
p = 0.001) [36].
While it was thought that deodorant (both metallic and
non-metallic) might have an undesirable effect on the skin,
there were no differences in a number of RISR outcomes
between those who wore deodorant or not as reported by
four trials [38-41]. Three studies [38-40] compared non-
metallic deodorant with no deodorant, while one study
[41] compared a deodorant containing 21% of aluminium
with no deodorant. A trial of 84 participants [40] reported
that deodorant could significantly reduce the incidence of
sweating at the end of the radiation treatment, but not at
the two-week follow-up (OR = 0.70, 95% CI −0.25 to 1.99,
p = 0.51).Steroidal topical treatment
A blinded RCT of 166 participants reported that topical
0.1% mometasone furoate cream was not superior to pla-
cebo for reducing the maximum level of RISR or RISR
level at two weeks after the end of treatment [44]. One
small RCT reported that 0.1% betamethasone cream was
effective for reducing the maximum level of RISR when
compared to placebo (MD −1.62, 95% CI −2.03 to −1.21,
p < 0.00001), and for reducing RISR severity at seven weeks
(two week follow-up) of radiation treatment (MD −0.55,
95% CI −0.71 to −0.39, p < 0.00001) [45]. One RCT [46],
with a small sample size of 21 participants, reported that
0.1% methylprednisolone was more effective than dex-
panthenol for reducing the levels of RISR at the two-week
follow-up post radiation treatment (p < 0.00001).Non-steroidal topical treatment
Two small-to-medium size blinded placebo RCTs [55,56]
reported the effectiveness of hyaluronic acid compared
with placebo for reducing the level of RISR severity at the
end of radiation treatment [56] (MD −0.73, 95% CI −1.04
to −0.42, p < 0.00001), at four weeks after radiationFigure 8 Forest plot of comparison: trolamine vs control. Outcome: M
possible range of 0-4.treatment completion [56] (MD −0.35, 95% CI −0.68 to
−0.02, p = 0.04) and the maximum level of RISR [55]
(MD-0.95, 95% CI −1.23 to −0.67, p < 0.00001). Addition-
ally, there were no statistically significant adverse effects of
hyaluronic acid compared to placebo [55,61]. However,
one trial [54] did not find that hyaluronic acid was effect-
ive for reducing the incidence of severe pain or quality of
life at week four of radiation treatment. One three-arm
RCT of a total of 68 participants [63] compared two for-
mulations with each other, and with no treatment. This
trial reported that formulation A topical cream (capprais
spinosa, opuntia coccinellifera and olive leaf extract) was
more effective than formulation B (non-steroidal water
based emulsion) for reducing the maximum RISR level
and the erythema index over a period of eight weeks.
Moreover, either formation was more effective than no
treatment for reducing these two outcomes [63].
According to the results of a fixed-effect meta-analysis,
trolamine was reported to not be more effective than usual
care (institutional preference) for reducing the maximum
level of RISR (MD 0.00, 95% CI −0.13 to 0.13, p = 0.97)
[48,49] (see Figure 8). When it was compared with placebo,
one trial [51] (n = 102) reported that participants found it
easier to use (MD 1.12, 95% CI 0.56 to 1.68, p < 0.00001)
and were more satisfied with trolamine (MD 0.44, 95% CI
0.01 to 0.87, p = 0.04). However, another non-blinded
RCT of 254 participants [60] reported that significantly
more patients in this trial rated calendula more difficult
to apply than trolamine (OR 7.68, 95% CI 3.07 to 19.17,
p < 0.0001). One multi-treatment arm trial [51] also re-
ported no statistically significant benefits of RadiaCare Gel
and Aquaphor ointment when individually compared to
placebo for reducing RISR, although the participants were
more satisfied with these two interventions, compared
with placebo topical preparations. According to the find-
ings from the analyses in this review, we were unable to
find any benefits of aloe vera gel and dexpanthenol, when
compared with placebo or no treatment. While a number
of trials individually reported statistically significant bene-
fits of using qingdiyou medication, wheatgrass extract
cream, and sucralfate cream for reducing RISR, we were
unable to conduct analysis due to inadequate data despite
attempts of contacting the trial authors.aximum levels of skin toxicity as measure by EORTC/RTOG, with a
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Two small non-blinded RCTs [69,70], with less than 40
participants in each trial, examined the effectiveness of
gentian violet dressings on time to healing when compar-
ing with a hydrogel dressing and non-adherent dressing.
The smaller trial (n = 20) reported results favouring the
hydrogel dressing (HR 7.95, 95% CI 2.20-28.68, p = 0.002),
with other trial (n = 39) reporting non-significant differ-
ence between the gentian violet dressing group and
non-adherent dressing group (HR 0.73, 95% CI 0.52-
1.03, p = 0.07). One trial [69] also reported there was no
statistically significant difference between the two dressings
in adverse effects. A small non-blinded RCT of 40 partici-
pants [71] reported that silver nylon dressing was more ef-
fective than standard care in reducing the level of RISR
severity at the end of radiation treatment (MD = −0.86,
95% CI −1.59 to −0.13, p = 0.02).
LED treatment versus Sham treatment
One small blinded RCT including 33 participants [74]
reported no benefits of LED for reducing the levels of
RISR at the end of radiation treatment (week five).
Discussion
The methodological quality of most of the RCTs was fair,
at best, with limitations in a number of domains. Another
limitation was the small number of studies per interven-
tion to perform meta-analyses. The largest meta-analysis
in this review only had 229 participants in the active treat-
ment arm and 223 participants in the control arm. In
some cases, meta-analysis was considered inappropriate as
the constituents of some topical applications varied be-
tween studies, as did the placebo creams; in trials that
compared dressings with standard care, the dressings were
made of different materials. Consequently, the evidence
was restricted to indirect comparisons between these var-
ied interventions. Additionally, as some therapies were
only tested on particular anatomical sites in populations
with mixed gender, age groups, and radiation techniques
and dosage, the evidence may be regarded as indirect for
other areas exposed to radiation. Taken together, these
limitations restrict confident decision making with regard
to the use of any of the included products to prevent RISR.
We were able to combine results for only four compari-
sons. Heterogeneity was absent in three of these but high
(I2 = 70%) in the comparison between Wobe-Mogus E ver-
sus usual care. The decision to combine results for trials
of Wobe-Mogus E, despite the high level of heterogeneity,
was based on the fact that results of both trials favoured
the intervention product and that heterogeneity was most
likely due to differences in dosing regimens. Confidence
intervals were wide for most of the comparisons included
in this review. The wide CIs are probably explained by
small sample sizes, indicating a high level of uncertaintyaround the effect sizes. Further research is, therefore,
very likely to have an important impact on the confi-
dence of the estimate of effect for most of the included
interventions.
Over the duration of the review, the research team made
a decision based on clinical reasons to include additional
outcomes concerning the time points of the RISR associ-
ated outcomes. The original time points were too rigid
and not necessarily the most clinically relevant, it was clin-
ically important for clinicians to assess RISR using the
maximum RISR levels and the levels of RISR at the end of
treatment and the last follow-up. The maximum level of
RISR represents the worst reaction associated with a given
intervention or no intervention at all. RISR levels at the
end of the radiation treatment and the last follow-up were
expected to be clinically relevant, and allowed the inclu-
sion of studies with differing end of treatment and follow
up times. These ‘follow-up’ time points are often the last
occasions of care for radiation oncologists, radiation on-
cology nurses, and radiation therapists.
Despite the potential limitations stated above, our re-
view represents the highest quality and most up-to-date
systematic review in this area and includes 47 RCTs of
5,688 participants. Whilst there have been a number of
systematic reviews published about the topic of RISRs,
these reviews have limited capacity for translation into
clinical practice due to significant methodological and de-
sign shortfalls [24]. For example, many of these systematic
reviews are out-dated and limit studies for inclusion to
those written in the English language. In light of these
common shortfalls across pre-existing publications on this
topic, this paper aims to provide an up-to-date systematic
review and meta-analysis of interventions that are cur-
rently utilised within clinical practice to prevent and
manage RISRs.
The results of review highlight that none of the studies
measured all outcomes of interest. Some non-clinical out-
comes (such as cost or costs associated treatment delay
and labour) can be important for clinical decision making.
Future trials should include these important outcomes.
Since the search of this review was conducted (11/2012),
at least three trials [75-77] relevant to the research ques-
tion of interest have been published. An RCT of 411 pa-
tients by Sharp et al. reported no significant difference
between Calendula Weleda® and Essex cream® in reducing
RISR [76]. Another double-blind RCT of 318 patients con-
ducted by Graham et al. also reported negative findings in
their RCT on the effects of a moisturizing durable barrier
cream and glycerine cream [75]. With regards to dress-
ings, a small unblinded RCT (n = 88) reported a signifi-
cant reduction in time to heal when Mepilex Lite dressing
was used in comparison with the usual care group [77].
The results of this review suggest that the evidence base is
extremely wide, with many interventions tested. However,
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few trials examining the effects of any single intervention.
Therefore, we do not expect the direction of recommen-
dation to change with the additional trials published over
this period. However, it is important that any subsequent
trials should be included in the future updates of the sys-
tematic review. Multiple high quality trials comparing
promising interventions are urgently needed.
Conclusion
This review found no strong evidence of effect for any of
the included trial products in reducing RISR. In practical
terms, the use of soap for washing did not show higher
levels of RISR compared with washing with water alone,
nor did the use of deodorants affect RISR levels. Conse-
quently, clinicians may advise patients to gently wash
affected areas with soap and water during their treat-
ment and that non-metallic deodorant use is not con-
traindicated. Further research is required to establish
whether metallic deodorants should be used. High quality,
well-powered studies are required to provide additional
evidence for the effectiveness of various products. In par-
ticular, efforts should focus on products which show
promise, such as Wobe-Mugos E and oral zinc for redu-
cing the RISR severity. Further research is also required to
understand which groups of patients may benefit from
topical corticosteroid treatment. There is also a lack of
well-powered RCTs comparing different types of dressings
for those who develop a desquamation requiring dressings.
Importantly, future trials should include outcomes such as
skin-specific quality of life, and costs.
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